Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma.

Yuan Z, Tian L, Wang P, Song Y, Dong Y, Zhuang H.

Onco Targets Ther. 2013 Oct 29;6:1527-32. doi: 10.2147/OTT.S51452. eCollection 2013.

2.

Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.

Que J, Kuo HT, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC.

BMC Cancer. 2016 Jul 12;16:451. doi: 10.1186/s12885-016-2512-x.

3.

Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: A pilot study.

Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kishimoto Y, Okubo Y, Makino H, Tsukamoto N, Igarashi Y, Sumino Y.

World J Gastroenterol. 2015 Dec 28;21(48):13490-9. doi: 10.3748/wjg.v21.i48.13490.

4.

Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases.

Yuan ZY, Meng MB, Liu CL, Wang HH, Jiang C, Song YC, Zhuang HQ, Yang D, Wang JS, Wei W, Li FT, Zhao LJ, Wang P.

Onco Targets Ther. 2014 Jun 12;7:915-23. doi: 10.2147/OTT.S58409. eCollection 2014.

5.

Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.

Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, Nakata R.

World J Gastroenterol. 2015 Dec 14;21(46):13101-12. doi: 10.3748/wjg.v21.i46.13101.

6.

Analysis of clinical efficacy of CyberKnife(®) treatment for locally advanced pancreatic cancer.

Song Y, Yuan Z, Li F, Dong Y, Zhuang H, Wang J, Chen H, Wang P.

Onco Targets Ther. 2015 Jun 12;8:1427-31. doi: 10.2147/OTT.S81939. eCollection 2015.

7.

Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.

Liu C, Sun L, Xu J, Zhao Y.

World J Surg Oncol. 2016 Apr 2;14:100. doi: 10.1186/s12957-016-0855-z.

8.

Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.

Bhandari RP, Stanford JD, Packianathan S, Duggar WN, Kanakamedala MR, Zhang X, Giri SP, Kumar PP, Harrell LM, Mangana SH, Yang C, Vijayakumar S.

Oncology. 2016;91(4):194-204. Epub 2016 Jul 19.

PMID:
27427761
9.

Evaluation of contrast-enhanced ultrasonography for hepatocellular carcinoma prior to and following stereotactic body radiation therapy using the CyberKnife® system: A preliminary report.

Shiozawa K, Watanabe M, Ikehara T, Kobayashi K, Ochi Y, Suzuki Y, Fuchinoue K, Yoneda M, Kenmochi T, Okubo Y, Mori T, Makino H, Tsukamoto N, Igarashi Y, Sumino Y.

Oncol Lett. 2016 Jan;11(1):208-212. Epub 2015 Nov 5.

10.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
11.

Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study.

Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M, Chen MS.

Radiology. 2012 Mar;262(3):1022-33. doi: 10.1148/radiol.11110817.

PMID:
22357902
12.

Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.

Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K.

Cochrane Database Syst Rev. 2013 Dec 19;(12):CD003046. doi: 10.1002/14651858.CD003046.pub3. Review.

PMID:
24357457
13.

Poor oncologic outcomes of hepatocellular carcinoma patients with intra-abdominal infection after hepatectomy.

Ruan DY, Lin ZX, Li Y, Jiang N, Li X, Wu DH, Wang TT, Chen J, Lin Q, Wu XY.

World J Gastroenterol. 2015 May 14;21(18):5598-606. doi: 10.3748/wjg.v21.i18.5598.

14.

[Treatment of postoperative recurrence of hepatocellular carcinoma with radiofrequency ablation comparing with repeated surgical resection].

Ren ZG, Gan YH, Fan J, Chen Y, Wu ZQ, Qin LX, Ge NL, Zhou J, Xia JL, Wang YH, Ye QH, Wang L, Ye SL.

Zhonghua Wai Ke Za Zhi. 2008 Nov 1;46(21):1614-6. Chinese.

PMID:
19094752
15.

Role of surgical resection for multiple hepatocellular carcinomas.

Choi SH, Choi GH, Kim SU, Park JY, Joo DJ, Ju MK, Kim MS, Choi JS, Han KH, Kim SI.

World J Gastroenterol. 2013 Jan 21;19(3):366-74. doi: 10.3748/wjg.v19.i3.366.

16.

Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.

Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.

J Vasc Interv Radiol. 2014 Feb;25(2):240-7. doi: 10.1016/j.jvir.2013.10.007. Epub 2013 Nov 28.

PMID:
24291001
17.

Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity.

Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X.

PLoS One. 2013 Oct 11;8(10):e77472. doi: 10.1371/journal.pone.0077472. eCollection 2013.

18.

Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.

Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD, Li LQ.

World J Gastroenterol. 2014 Dec 7;20(45):17141-7. doi: 10.3748/wjg.v20.i45.17141.

19.

Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases.

Wang Z, Kong QT, Li J, Wu XH, Li B, Shen ZT, Zhu XX, Song Y.

J Thorac Dis. 2015 Mar;7(3):407-12. doi: 10.3978/j.issn.2072-1439.2015.01.09.

20.

CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC?

Schoenberg M, Khandoga A, Stintzing S, Trumm C, Schiergens TS, Angele M, Op den Winkel M, Werner J, Muacevic A, Rentsch M.

Cureus. 2016 Apr 28;8(4):e591. doi: 10.7759/cureus.591.

Supplemental Content

Support Center